Back to News
Market Impact: 0.2
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
The company announced its second priority review voucher (PRV) sale within one week, following its previously announced GENGLYCOS™ PRV transaction. The article provides no sale value or other transaction details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Anthropic's third-quarter revenue is said to hit $16.8 billion ahead of IPO
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Netwealth stock sliding today?
- Bending Spoons skyrockets 35% as Berkshire Hathaway makes $330 million investment
- Bending Spoons Stock Soars on Berkshire’s Increased Stake